Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz gmbh - rivaroxaban 15 mg - comprimé pelliculé - 15 mg - rivaroxaban 15 mg - rivaroxaban

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz gmbh - rivaroxaban 20 mg - comprimé pelliculé - 20 mg - rivaroxaban 20 mg - rivaroxaban

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz gmbh - rivaroxaban 15 mg (comprimé rouge 15 mg); rivaroxaban 20 mg (comprimé brun-rouge 20 mg) - comprimé pelliculé - 15 mg + 20 mg - rivaroxaban 15 mg; rivaroxaban 20 mg - rivaroxaban

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - rivaroxabanum - rivaroxaban-mepha vascular 2.5 mg filmtabletten - rivaroxabanum 2.5 mg, natrii laurilsulfas, lactosum monohydricum 184.7 mg, hypromellosum, carmellosum natricum conexum, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 172 (flavum), pro compresso obducto corresp. natrium max. 1.19 mg. - en association avec l'acide acétylsalicylique en prévention de graves événements athérothrombotiques Événements chez les patients atteints de maladie coronarienne ou avérée artérielle périphérique vaisseaux et à un risque élevé d'Événements ischémiques - synthetika

Union européenne - français - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - agents antithrombotiques - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Union européenne - français - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - agents antithrombotiques - prévention de la thromboembolie veineuse (tev) chez les patients adultes subissant une chirurgie élective de remplacement de la hanche ou du genou. le traitement de la thrombose veineuse profonde (tvp) et l'embolie pulmonaire (ep) et prévention des récidives de tvp et l'ep chez les adultes. (see section 4. 4 for haemodynamically unstable pe patients. le traitement de la thrombose veineuse profonde (tvp) et l'embolie pulmonaire (ep) et prévention des récidives de tvp et l'ep chez les adultes. (see section 4. 4 pour en présentant des répercussions hémodynamiques instables pe malades). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. le traitement de la thrombose veineuse profonde (tvp) et l'embolie pulmonaire (ep) et prévention des récidives de tvp et l'ep chez les adultes. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 et 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. le traitement de la thrombose veineuse profonde (tvp) et l'embolie pulmonaire (ep) et prévention des récidives de tvp et l'ep chez les adultes. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Canada - français - Health Canada

pharmascience inc - rivaroxaban - comprimé - 10mg - rivaroxaban 10mg

Canada - français - Health Canada

pharmascience inc - rivaroxaban - comprimé - 15mg - rivaroxaban 15mg

Canada - français - Health Canada

pharmascience inc - rivaroxaban - comprimé - 20mg - rivaroxaban 20mg

Canada - français - Health Canada

dr reddy's laboratories ltd - rivaroxaban - comprimé - 2.5mg - rivaroxaban 2.5mg